Literature DB >> 23018033

Considerations on safety concerns about citalopram prescribing.

Robert D Sheeler1, Michael J Ackerman, Elliott Richelson, Thomas K Nelson, Jeffrey P Staab, Eric G Tangalos, Lisa M Dieser, Julie L Cunningham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23018033      PMCID： PMC3532688          DOI： 10.1016/j.mayocp.2012.07.009

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  7 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

Review 3.  Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.

Authors:  Ping-Tao Tseng; Yu Lee; Ya-En Lin; Pao-Yen Lin
Journal:  Gen Hosp Psychiatry       Date:  2011-11-30       Impact factor: 3.238

Review 4.  Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

Authors:  Maurizio Fava; A John Rush; Madhukar H Trivedi; Andrew A Nierenberg; Michael E Thase; Harold A Sackeim; Frederic M Quitkin; Steven Wisniewski; Philip W Lavori; Jerrold F Rosenbaum; David J Kupfer
Journal:  Psychiatr Clin North Am       Date:  2003-06

5.  A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.

Authors:  Kari Laine; Umit Yasar; Jolanta Widén; Gunnel Tybring
Journal:  Pharmacol Toxicol       Date:  2003-08

6.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

7.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Authors:  A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe
Journal:  Control Clin Trials       Date:  2004-02
  7 in total
  2 in total

1.  Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder.

Authors:  Li-Ming Zhang; Wen-Wen Zhou; Ya-Jun Ji; Ying Li; Nan Zhao; Hong-Xia Chen; Rui Xue; Xin-Guo Mei; You-Zhi Zhang; Heng-Lin Wang; Yun-Feng Li
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

2.  Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders.

Authors:  Mirjam Simoons; Hans Mulder; Bennard Doornbos; Robert A Schoevers; Eric N van Roon; Henricus G Ruhé
Journal:  PLoS One       Date:  2018-08-21       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.